SCHEMBL1657100

SCHEMBL1657100

Cc1cccc(C)c1Oc1ccc2c(c1)C(=O)N(CC(=O)O)C2=O

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.72
LPAR3 Q9UBY5 2/20 0.72
LPAR1 Q92633 1/20 0.72
KMT2A Q03164 5/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
MEN1 O00255 4/20 0.53
CA12 O43570 1/20 0.51
CA9 Q16790 1/20 0.51
HSD17B10 Q99714 3/20 0.49
HPGD P15428 2/20 0.49
KDM4E B2RXH2 3/20 0.46
ALDH1A1 P00352 3/20 0.46
HTT P42858 1/20 0.46
CYP1A2 P05177 1/20 0.46
MAPT P10636 1/20 0.46
AKR1B1 P15121 1/20 0.46
ALOX15 P16050 1/20 0.46
MAPK1 P28482 1/20 0.45
FFAR1 O14842 1/20 0.45
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1655994 0.92 LPAR3 (0.65) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL1656185 0.90 LPAR3 (0.76) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL523290 0.88 KMT2A (0.57) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL1656856 0.88 TDP1 (0.69) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL15271754 0.86 KMT2A (0.78) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL20846409 0.84 LPAR3 (1.00) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL523652 0.82 TDP1 (0.88) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL1656858 0.80 KMT2A (0.52) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL28634112 0.80 TDP1 (0.77) TDP1LPAR3LPAR1KMT2ASMN1; SMN2
SCHEMBL13187733 0.79 TDP1 (0.77) TDP1LPAR3LPAR1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160009653-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2016-01-14 US disclosed
US-9174976-B2 Cyanoisoquinoline compounds and methods of use thereof FIBROGEN, INC. (US) 2015-11-03 US disclosed
US-20150031696-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. (US) 2015-01-29 US disclosed
US-8759373-B2 Cyanoisoquinoline compounds and methods of use thereof FIBROGEN, INC. (US) 2014-06-24 US disclosed
EP-2476669-A1 Cyanoisoquinoline compounds and methods of use thereof Fibrogen, Inc. (US) 2012-07-18 EP disclosed
US-20120178755-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2012-07-12 US disclosed
EP-2044028-B1 CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) FIBROGEN INC (US) 2012-05-16 EP disclosed
US-20110212959-A1 Cyanoisoquinoline Compounds and Methods of Use Thereof FIBROGEN, INC. 2011-09-01 US disclosed
US-7928120-B2 Cyanoisoquinoline compounds and methods of use thereof FIBROGEN, INC. (US) 2011-04-19 US disclosed
EP-2044028-A2 CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) FIBROGEN, INC. (US) 2009-04-08 EP disclosed
US-20070298104-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF FIBROGEN, INC. 2007-12-27 US disclosed
WO-2007090068-A2 CYANOISOQUINOLINE COMPOUNDS THAT STABILIZE HYPOXIA INDUCIBLE FACTOR (HIF) FIBROGEN, INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160009653-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 TDP1 4029/4885LPAR3 3272/4885LPAR1 3708/4885
US-20070298104-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 TDP1 4201/4885LPAR3 3295/4885LPAR1 3790/4885
US-20120178755-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 TDP1 4201/4885LPAR3 3295/4885LPAR1 3790/4885
US-20150031696-A1 CYANOISOQUINOLINE COMPOUNDS AND METHODS OF USE THEREOF HIF1AN, HIF1A, EGLN3 TDP1 4201/4885LPAR3 3295/4885LPAR1 3790/4885
US-20110212959-A1 Cyanoisoquinoline Compounds and Methods of Use Thereof HIF1AN, HIF1A, EGLN3 TDP1 4201/4885LPAR3 3295/4885LPAR1 3790/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.